Bortezomib Injection, Powder, Lyophilized, For Solution
Product Images NDC 75007-501

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Bortezomib (NDC 75007-501). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ningbo Shuangcheng Pharmaceutical Co., Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Bortezomib0010)

Bortezomib 3.5 mg vial packaging label for injection, powder, lyophilized, for solution by Ningbo Shuangcheng Pharmaceutical Co., Ltd. The label includes reconstitution information detailing volumes for subcutaneous (1.4 mL) and intravenous (3.5 mL) use with respective dosages. It specifies storage conditions and that the product is for intravenous or subcutaneous use with a single-dose vial.*

FDA Label Image

Image Description (Bortezomib008)

Bortezomib 3.5 mg/vial injection label for lyophilized powder for solution. The label includes directions indicating it is for single-dose use and intended for intravenous or subcutaneous use only. The storage instructions specify 2 to 25°C (36 to 77°F) with allowable excursions. Manufactured by Ningbo Shuangcheng Pharmaceutical Co., Ltd. The label also displays the product NDC 75007-501-32 and a barcode.*

FDA Label Image

Image Description (Bortezomib009)

The packaging label for Bortezomib Injection, powder, lyophilized for solution, 3.5 mg per vial from Ningbo Shuangcheng Pharmaceutical Co., Ltd. The label includes dosage reconstitution instructions for subcutaneous and intravenous use, specifies single-dose vial use, and features the product NDC 75007-501-32. The label has sections detailing contents, storage, and manufacturer address.*

FDA Label Image

Image Description (Bortezomib02)

A Kaplan-Meier survival curve comparing percentage of patients over time (months) between two treatment groups labeled Vc-MP (red line) and MP (blue line). The x-axis represents time in months up to 26 months, and the y-axis shows the percentage of patients from 0 to 100%. The chart includes patient counts at risk for each group at various time points and a p-value indicating statistical comparison between groups.*

FDA Label Image

Image Description (Bortezomib03)

A Kaplan-Meier survival curve depicting the percentage of patients over time (months) for two treatment groups labeled Vc-MP and MP. The graph shows higher survival percentages for Vc-MP compared to MP over 78 months. A p-value less than 0.05 is indicated, suggesting statistical significance in the difference between the two groups. The graph includes a table of numbers at risk over time below the x-axis.*

FDA Label Image

Image Description (Bortezomib04)

A Kaplan-Meier survival curve graph comparing the proportion of patients over time (days) for Bortezomib and Dexamethasone treatments. The y-axis represents the proportion of patients, and the x-axis shows time in days up to 450 days. Bortezomib and Dexamethasone are represented by distinct lines illustrating patient survival trends, with a p-value indicating statistical significance. Below the x-axis are patient counts at various time points for each treatment.*

FDA Label Image

Image Description (Bortezomib05)

A Kaplan-Meier survival curve chart showing the proportion of patients over time (days) comparing Bortezomib and Dexamethasone treatments. The y-axis represents the proportion of patients and the x-axis shows time in days up to 490 days. Bortezomib is represented by a blue line with circles, and Dexamethasone by a red line with triangles. Patient numbers at different time points are noted below the graph, along with a p-value indicating statistical significance.*

FDA Label Image

Image Description (Bortezomib06)

This is a Kaplan-Meier survival curve graph comparing the percentage of patients over time (in months) between two groups labeled VcR-CAP and R-CHOP. The graph includes a p-value from the log rank test (<0.001) indicating statistical comparison between these groups, with a table showing the number of subjects at risk at various time points.*

FDA Label Image

Image Description (Bortezomib07)

A survival curve chart showing the percentage of subjects alive over months from randomization, comparing two groups: VcR-CAP (solid line) and R-CHOP (dashed line). The chart includes a hazard ratio with 95% confidence interval, and a table of subjects at risk at various time points for each group.*

FDA Label Image

Image Description (Bortezomib01)

Chemical structure of Bortezomib, showing its molecular framework including boronic acid groups, amide bonds, and aromatic rings, consistent with its identity as the active ingredient in Bortezomib injection powder, lyophilized, for solution.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.